PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Critical exploration of co-occurring Attention-Deficit/Hyperactivity Disorder, mood disorder and Substance Use Disorder.

Abstract Co-occurring disorders (CODs) describe a Substance Use Disorder (SUD) accompanied by a comorbid psychiatric disorder. Attention-Deficit/Hyperactivity Disorder (ADHD) and mood disorders are common CODs with high prevalence rates in SUD populations. It is proposed that literature on a tri-condition presentation of ADHD, mood disorder and SUD is limited. Areas covered: A literature search was conducted using a keyword search on EBSCOhost. Initially 2 799 records were identified, however, only two articles included all three conditions occurring concurrently in individuals. CODs constitute a major concern due to their overarching burden on society as a whole. Diagnosis and treatment of such patients is challenging. There is evidence that dysfunction of dopamine in the brain reward circuitry impacts the development or symptomology of all three disorders. Disparity exists regarding whether ADHD or mood disorders are greater modifiers for increased SUD severity. However, it has been reported that poor functional capacity may have a greater influence than comorbidities on SUD development. Expert commentary: Challenges exist which confound the clear distinction of CODs, however, with greater emergence of adult ADHD its screening in SUD populations should become standard practice to establish data on multi-condition presentations with the ultimate goal of improving clinical outcomes.
PMID
Related Publications

Co-occurring mental and substance use disorders: the neurobiological effects of chronic stress.

Need for care and life satisfaction in adult substance use disorder patients with and without attention deficit hyperactivity disorder (ADHD) or autism spectrum disorder (ASD).

Prevalence of attention-deficit hyperactivity disorder in substance use disorder patients: a meta-analysis and meta-regression analysis.

The complicated relationship between attention deficit/hyperactivity disorder and substance use disorders.

Everyday life consequences of substance use in adult patients with a substance use disorder (SUD) and co-occurring attention deficit/hyperactivity disorder (ADHD) or autism spectrum disorder (ASD): a patient's perspective.

Authors

Mayor MeshTerms
Keywords

Adults

Attention-Deficit/Hyperactivity Disorder (ADHD)

Substance Use Disorder (SUD)

bipolar disorder

co-occurring disorders

dysthymia

major depressive disorder

mood disorder

substance abuse

Journal Title expert review of pharmacoeconomics & outcomes research
Publication Year Start




PMID- 28686107
OWN - NLM
STAT- MEDLINE
DA  - 20170707
DCOM- 20170804
LR  - 20170804
IS  - 1744-8379 (Electronic)
IS  - 1473-7167 (Linking)
VI  - 17
IP  - 3
DP  - 2017 Jun
TI  - Critical exploration of co-occurring Attention-Deficit/Hyperactivity Disorder,
      mood disorder and Substance Use Disorder.
PG  - 275-282
LID - 10.1080/14737167.2017.1351878 [doi]
AB  - INTRODUCTION: Co-occurring disorders (CODs) describe a Substance Use Disorder
      (SUD) accompanied by a comorbid psychiatric disorder.
      Attention-Deficit/Hyperactivity Disorder (ADHD) and mood disorders are common
      CODs with high prevalence rates in SUD populations. It is proposed that
      literature on a tri-condition presentation of ADHD, mood disorder and SUD is
      limited. Areas covered: A literature search was conducted using a keyword search 
      on EBSCOhost. Initially 2 799 records were identified, however, only two articles
      included all three conditions occurring concurrently in individuals. CODs
      constitute a major concern due to their overarching burden on society as a whole.
      Diagnosis and treatment of such patients is challenging. There is evidence that
      dysfunction of dopamine in the brain reward circuitry impacts the development or 
      symptomology of all three disorders. Disparity exists regarding whether ADHD or
      mood disorders are greater modifiers for increased SUD severity. However, it has 
      been reported that poor functional capacity may have a greater influence than
      comorbidities on SUD development. Expert commentary: Challenges exist which
      confound the clear distinction of CODs, however, with greater emergence of adult 
      ADHD its screening in SUD populations should become standard practice to
      establish data on multi-condition presentations with the ultimate goal of
      improving clinical outcomes.
FAU - Regnart, Judith
AU  - Regnart J
AD  - a Drug Utilization Research Unit (DURU), Department of Pharmacy , Nelson Mandela 
      Metropolitan University , Port Elizabeth , South Africa.
FAU - Truter, Ilse
AU  - Truter I
AD  - a Drug Utilization Research Unit (DURU), Department of Pharmacy , Nelson Mandela 
      Metropolitan University , Port Elizabeth , South Africa.
FAU - Meyer, Anneke
AU  - Meyer A
AD  - b Department of Psychology , Nelson Mandela Metropolitan University , Port
      Elizabeth , South Africa.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170713
PL  - England
TA  - Expert Rev Pharmacoecon Outcomes Res
JT  - Expert review of pharmacoeconomics & outcomes research
JID - 101132257
RN  - VTD58H1Z2X (Dopamine)
SB  - IM
MH  - Animals
MH  - Attention Deficit Disorder with
      Hyperactivity/*epidemiology/physiopathology/therapy
MH  - Brain/metabolism/physiopathology
MH  - Diagnosis, Dual (Psychiatry)
MH  - Dopamine/metabolism
MH  - Humans
MH  - Mood Disorders/*epidemiology/physiopathology/therapy
MH  - Prevalence
MH  - Reward
MH  - Severity of Illness Index
MH  - Substance-Related Disorders/*epidemiology/physiopathology/therapy
OTO - NOTNLM
OT  - Adults
OT  - Attention-Deficit/Hyperactivity Disorder (ADHD)
OT  - Substance Use Disorder (SUD)
OT  - bipolar disorder
OT  - co-occurring disorders
OT  - dysthymia
OT  - major depressive disorder
OT  - mood disorder
OT  - substance abuse
EDAT- 2017/07/08 06:00
MHDA- 2017/08/05 06:00
CRDT- 2017/07/08 06:00
AID - 10.1080/14737167.2017.1351878 [doi]
PST - ppublish
SO  - Expert Rev Pharmacoecon Outcomes Res. 2017 Jun;17(3):275-282. doi:
      10.1080/14737167.2017.1351878. Epub 2017 Jul 13.